DLL4 Protein, Human, Recombinant (hFc)

DLL4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 81 kDa and the accession number is Q9NR61.

DLL4 Protein, Human, Recombinant (hFc)

パッケージサイズ	在庫状況	単価(税別)
50 μg	在庫あり	￥ 52,500
100 μg	約5 days	￥ 93,000
200 μg	約5 days	￥ 164,500
500 μg	約5 days	￥ 349,000

バルクのお問い合わせ

生物学的情報

1. Measured by its binding ability in a functional ELISA. Immobilized Mouse NOTCH1-His at 2 μg/ml (100 μl/well) can bind human DLL4-hFc , the EC50 of human DLL4-hFc is 15-90 ng/mL. 2. Measured by the ability of the immobilized protein to enhance BMP2-induced alkaline phosphatase activity in C3H10T1/2 mouse embryonic fibroblast cells. The ED50 for this effect is typically 1-8 µg/mL in the presence of 500 ng/mL recombinant human BMP2.

説明

DLL4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 81 kDa and the accession number is Q9NR61.

Species	Human
Expression Host	HEK293 Cells
Tag	C-hFc
Accession Number	Q9NR61
別名	δ-like 4 (Drosophila), Delta-like 4, hdelta2, delta-like 4 (Drosophila), hδ2, δ-like 4
Construction	The extracellular domain (Met1-Pro524) of Human DLL4 (NP_061947.1) was expressed with the Fc region of Human IgG1 at the C-terminus.
Protein Purity	≥ 95 % as determined by SDS-PAGE. ≥ 85 % as determined by SEC-HPLC.
分子量	81 kDa (predicted)

Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

参考文献

1. Yan M,et al.(2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6. 2. Sainson RC,et al.(2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95. 3. Martinez JC,et al.(2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606. 4. Li JL,et al.(2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.

Calculator

Reconstitution Calculator

Recombinant Proteins Dilute Calculator

Specific Activity Calculator

bottom

DLL4 Protein, Human, Recombinant (hFc)

参考文献

Calculator

技術サポート

Keywords